PTC Lycosome

**PTC Lycosome** is a Lycotec-developed lycosome formulation of **phosphatidylcholine** designed for metabolic liver and pancreatic fat disorders, including **nonalcoholic fatty liver disease**, **nonalcoholic steatohepatitis**, and **pancreatic steatosis**. The product appears to be an **oral nutraceutical drug candidate** in which phosphatidylcholine is encapsulated within **lycopene-based lycosomes** to protect the cargo from gastric acidity and intestinal degradation and thereby improve systemic delivery and bioavailability. Publicly available context indicates proof-of-concept **Phase 2** development by Lycotec for NAFLD/NASH and pancreatic steatosis. Its proposed therapeutic effect is not based on a single validated receptor target, but on enhanced delivery of phosphatidylcholine to support hepatic lipid handling, membrane phospholipid replenishment, and improvement of steatosis-associated metabolic parameters.

Other names

lycosome-formulated phosphatidylcholinephosphatidylcholine lycosomephosphatidylcholine in lycopene-based lycosomes